Coronavirus illness 2019 (COVID-19) is an infectious illness precipitated by the newly found coronavirus, SARS-CoV-2. Increased severity of COVID-19 has been noticed in sufferers with diabetes mellitus (DM). This research aimed to determine common transcriptional signatures, regulators and pathways between COVID-19 and DM. We have built-in human whole-genome transcriptomic datasets from COVID-19 and DM, adopted by practical evaluation with gene ontology (GO) and pathway analyses.
In peripheral blood mononuclear cells (PBMCs), among the many upregulated differentially expressed genes (DEGs), 32 had been discovered to be generally modulated in COVID-19 and sort 2 diabetes (T2D), whereas 10 DEGs had been generally downregulated. As regards sort 1 diabetes (T1D), 21 DEGs had been generally upregulated, and 29 DEGs had been generally downregulated in COVID-19 and T1D. Moreover, 35 DEGs had been generally upregulated in SARS-CoV-2 contaminated pancreas organoids and T2D islets, whereas 14 had been generally downregulated.
Several GO phrases had been present in common between COVID-19 and DM. Prediction of the putative transcription components concerned within the upregulation of genes in COVID-19 and DM recognized RELA to be implicated in each PBMCs and pancreas. Here, for the primary time, we have now characterised the organic processes and pathways generally dysregulated in COVID-19 and DM, which might be within the subsequent future used for the design of customized remedy of COVID-19 sufferers affected by DM as comorbidity.
Cisplatin’s potential for sort 2 diabetes repositioning by inhibiting CDKN1A, FAS, and SESN1
Cisplatin is a DNA-damaging chemotherapeutic agent used for treating most cancers. Based on cDNA dataset analysis, we investigated how cisplatin modified gene expression and noticed cisplatin-induced dysregulation and system-level variations referring to insulin resistance and sort 2 diabetes mellitus (T2DM). T2DM is a multifactorial illness affecting 462 million individuals on the planet, and drug-induced T2DM is a severe problem.
To perceive this etiology, we designed an integrative, system-level research to determine associations between cisplatin-induced differentially expressed genes (DEGs) and T2DM. From an inventory of differential expressed genes, cisplatin downregulated the cyclin-dependent kinase inhibitor 1 (CDKN1A), tumor necrosis issue (FAS), and sestrin-1 (SESN1) genes chargeable for modifying signaling pathways, together with the p53, JAK-STAT, FOXO, MAPK, mTOR, P13-AKT, Toll-like receptor (TLR), adipocytokine, and insulin signaling pathways. These enriched pathways had been expressively related to the illness.
We noticed important gene signatures, together with SMAD3, IRS, PDK1, PRKAA1, AKT, SOS, RAS, GRB2, MEK1/2, and ERK, interacting with supply genes. This research revealed the worth of system genetics for figuring out the cisplatin-induced genetic variants chargeable for the development of T2DM. Also, by cross-validating gene expression information for T2DM islets, we discovered that downregulating IRS and PRK households is important in insulin and T2DM signaling pathways.
Cisplatin, by inhibiting CDKN1A, FAS, and SESN1, promotes IRS and PRK exercise in the same technique to rosiglitazone (a preferred drug used for T2DM remedy). Our integrative, network-based strategy might help in understanding the drug-induced pathophysiological mechanisms of diabetes.
Relationship between cardiovascular and kidney disease in a sample of patients with diabetes in today’s world
Kidney disease is one of the microvascular complications of diabetes mellitus (DM) with little research and a great relationship with cardiovascular disease (CVD). The objective of this work is to characterize the prevalence of kidney disease in a population of patients with type 2 diabetes who attend outpatient management by cardiology, determine its degree of investigation and its possible effect on the achievement of therapeutic objectives and the use of antidiabetics with cardiorenal protective effect.
Methods: Cross-sectional, observational and multicenter study carried out in 44 centers in Argentina between May and July 2019. Results: 693 patients were included with an established CVD prevalence of 47.5% (329 patients) and 42.3% of microvascular disease . Albuminuria was only assessed in 46.2% of the patients and it was significantly higher in the group with IR. CVD in patients with IR was higher than in those without IR (64.8% vs. 42.2%; p = 0.0001). The presence of albuminuria was accompanied by a higher prevalence of CVD.
The scope of the therapeutic targets was limited and no differences were recognized as a function of RI, with the exception of the LDL target. Low prescription of antidiabetic drugs with proven cardiorenal benefit was observed. Conclusions: The work highlights the importance of the active search for kidney disease in patients with diabetes, which reveals the low scope of therapeutic goals and the prescription of antidiabetic drugs with cardiorenal benefit.
Evaluation of affiliation research and a scientific evaluation and meta-analysis of VDR polymorphisms in sort 2 diabetes mellitus threat
Numerous unique research and four revealed meta-analyses have reported the affiliation between the Vitamin D receptor (VDR) BsmI, FokI, ApaI, and TaqI polymorphisms and sort 2 diabetes mellitus (T2DM) threat. However, the outcomes had been inconsistent.
Therefore, an up to date meta-analysis was carried out to additional discover these points.To additional discover the affiliation between the VDR BsmI, FokI, ApaI, and TaqI polymorphisms and T2DM threat.PubMed, EMBASE, Scopus, and Wanfang databases had been searched. The following search technique had been used: (VDR OR vitamin D receptor) AND (polymorphism OR variant OR mutation) AND (diabetes OR mellitus OR diabetes mellitus).
Pooled crude odds ratios with 95% confidence intervals had been utilized to guage the energy of affiliation in 5 genetic fashions. Statistical heterogeneity, the take a look at of publication bias, and sensitivity analysis had been carried out utilizing the STATA software program (Version 12.0). To consider the credibility of statistically important associations, we utilized the false-positive report chances (FPRP) and Bayesian false discovery chance (BFDP) take a look at.
Overall, the VDR BsmI polymorphism was related to a considerably decreased T2DM threat in Asians; the VDR FokI polymorphism was related to a considerably decreased T2DM threat in Asians, African international locations, and Asian international locations; the VDR ApaI polymorphism was related to a considerably decreased T2DM threat in Caucasians and North American international locations.On the VDR ApaI polymorphism, a considerably elevated T2DM threat was present in a blended inhabitants.
HeLa Cell Extract |
|||
| 30R-AG012 | Fitzgerald | 100 ug | 418.8 EUR |
|
Description: Glutathiolated human epithelial carcinoma cell (HeLa) extract |
|||
HeLa Cell Slide |
|||
| 17-001 | ProSci | 1 pack | 216.6 EUR |
|
Description: HeLa S3 (cervix; adenocarcinoma) |
|||
cDNA from Human Tumor Cell Line: Hela |
|||
| C1255811 | Biochain | 40 reactions | 451.2 EUR |
|
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
|||
Inducible GFP Hela stable cell line |
|||
| SC036 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
|
Description: InducibleGFP expression stable cell line in Hela cells, with Neomycin and puromycin resitance |
|||
Inducible RFP Hela stable cell line |
|||
| SC037 | GenTarget | 2 x 106 cell/ml x 1ml | 1800 EUR |
|
Description: Inducible RFP expression stable cell line in Hela with Blasticidin and Puromycin resistance |
|||
Hela / Cas9 (Bad) Stable Cell Line |
|||
| SC045-Cas9-Bsd | GenTarget | 2 x 106 cell/ml x 1ml | 1269.6 EUR |
|
Description: Cas9 expression stable cell line with Blasticidin resistance in Hela human cervical cancer cells. |
|||
Gene Knock-Out HR Targeting Vector [MCS1-EF1?-RFP-T2A-Puro-pA-MCS2] |
|||
| HR110PA-1 | SBI | 10 ug | 1227.6 EUR |
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-GFP-T2A-Puro-pA-MCS2] |
|||
| HR410PA-1 | SBI | 10 ug | 1227.6 EUR |
Gene Knock-Out HR Targeting Vector [MCS1-EF1a-RFP-T2A-Hygro-pA-MCS2] |
|||
| HR510PA-1 | SBI | 10 ug | 1227.6 EUR |
Human Hela Whole Cell Lysate |
|||
| LYSATE0023 | BosterBio | 200ug | 180 EUR |
|
Description: This cell lysate is prepared from human hela using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C. |
|||
TARGATT? Knock-in iPSC Generation (Master Cell Line) |
|||
| AST-1100 | Applied StemCell | 1 vial of 1X10^6 cells | Ask for price |
|
Description: 6 month |
|||
H2O2 stimulated HeLa Cell Lysate (Human epithelial cell line) |
|||
| LF-R0002 | Abfrontier | Each 100 ul | 145.2 EUR |
|
Description: HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate - H2O2 stimulated |
|||
Genomic DNA from Human Tumor Cell Line: Hela |
|||
| D1255811 | Biochain | 100 ug | 291.6 EUR |
|
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes. |
|||
Total Protein from Human Tumor Cell Line: Hela |
|||
| P1255811 | Biochain | 1 mg | 256.8 EUR |
|
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation. |
|||
Membrane Protein from Human Tumor Cell Line: Hela |
|||
| P3255811 | Biochain | 0.1 mg | 342 EUR |
|
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation. |
|||
Total RNA from Human Tumor Cell Line: Hela |
|||
| R1255811-50 | Biochain | 50 ug | 232.8 EUR |
|
Description: Can be used for various studies in the realm of gene expression and regulation, both normal and pathological. It is an excellent control and suitable for educational purposes. |
|||
TARGATT? Knock-in Mouse Cell Line Generation Kit (Master Cell Line) |
|||
| AST-7001 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 6 month |
|||
Rrad/ Rat Rrad ELISA Kit |
|||
| ELI-14921r | Lifescience Market | 96 Tests | 1063.2 EUR |
HeLa Cell Lysate (Whole Cell) |
|||
| LYSATE0001 | Cusabio | 200ug | 180 EUR |
|
Description: This whole cell lysate is prepared from Hela cells using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C. |
|||
Human ; HeLa (#1) |
|||
| 02-723 | Sceti | 100ng | 481.2 EUR |
|
Description: The Human ; HeLa (#1) is available in Europe and for worldwide shipping via Gentaur. |
|||
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU269725 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR Luciferase Stable Cell Line |
|||
| TU022380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU219725 | ABM | 1.0 ml | Ask for price |
RRAD 3'UTR GFP Stable Cell Line |
|||
| TU072380 | ABM | 1.0 ml | 1672.8 EUR |
Rrad 3'UTR GFP Stable Cell Line |
|||
| TU168183 | ABM | 1.0 ml | Ask for price |
Rrad 3'UTR Luciferase Stable Cell Line |
|||
| TU118183 | ABM | 1.0 ml | Ask for price |
TARGATT? Knock-in CHO Generation Kit (Master Cell Line) |
|||
| AST-1200 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
TARGATT? Knock-in HEK293 Generation Kit (Master Cell Line) |
|||
| AST-1300 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
RRAD Peptide |
|||
| 43-008P | ProSci | 0.1 mg | 405.6 EUR |
|
Description: RRAD Peptide |
|||
RRAD antibody |
|||
| 70R-50359 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal RRAD antibody |
|||
RRAD antibody |
|||
| 70R-5797 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD antibody |
|||
| 70R-5798 | Fitzgerald | 50 ug | 560.4 EUR |
|
Description: Rabbit polyclonal RRAD antibody raised against the middle region of RRAD |
|||
RRAD Antibody |
|||
| 37229-100ul | SAB | 100ul | 302.4 EUR |
RRAD Antibody |
|||
| 1-CSB-PA779820 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
|||
RRAD siRNA |
|||
| 20-abx932133 | Abbexa |
|
|
RRAD Antibody |
|||
| CSB-PA233809-100ul | Cusabio | 100ul | 379.2 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
RRAD Antibody |
|||
| 1-CSB-PA248209 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
|||
RRAD Antibody |
|||
| 1-CSB-PA003910 | Cusabio |
|
|
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
|||
RRAD Antibody |
|||
| R34275-100UG | NSJ Bioreagents | 100 ug | 399 EUR |
RRAD Antibody |
|||
| CSB-PA233809- | Cusabio | each | 402 EUR |
|
Description: A polyclonal antibody against RRAD. Recognizes RRAD from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:3000, IHC:1:50-1:100, IF:1:100-1:500 |
|||
HeLa cells |
|||
| C0008001 | Addexbio | One Frozen vial | 546 EUR |
RRAD sgRNA CRISPR Lentivector set (Human) |
|||
| K2069901 | ABM | 3 x 1.0 ug | 406.8 EUR |
Cas9-Expressing HeLa Cell Pool |
|||
| 78161 | BPS Bioscience | 2 vials | 795 EUR |
|
Description: Cas9 (Streptococcus pyogenes CRISPR associated protein 9) is an endonuclease enzyme that, when recruited to a specific DNA sequence by the sgRNA (single guide RNA), introduces a double stranded break into the DNA. This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the targeted gene. Cas9-expressing HeLa cells can be transduced or electroporated with sgRNA targeting a gene of interest to quickly generate knock-out cell pools or cell lines. |
|||
Basic HR Targeting Vector [MCS1-LoxP-MCS2-MCS3-pA-LoxP-MCS4] for Gene Knock-In/Out |
|||
| HR100PA-1 | SBI | 10 ug | 1125.6 EUR |
Human RRAD shRNA Plasmid |
|||
| 20-abx954199 | Abbexa |
|
|
RRAD ELISA KIT|Human |
|||
| EF005507 | Lifescience Market | 96 Tests | 826.8 EUR |
RRAD Recombinant Protein (Human) |
|||
| RP095493 | ABM | 100 ug | Ask for price |
Human HeLa Whole Cell Lysate, TNFa Stimulated |
|||
| HCL-2000 | Alpha Diagnostics | 100ug | 255.6 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract |
|||
| HCL-2008 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate |
|||
| HCL-2009 | Alpha Diagnostics | 1 mg | 628.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2069902 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2069903 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2069904 | ABM | 1.0 ug DNA | 184.8 EUR |
RRAD Blocking Peptide |
|||
| 33R-10070 | Fitzgerald | 100 ug | 216 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5798 |
|||
RRAD Blocking Peptide |
|||
| 33R-4793 | Fitzgerald | 100 ug | 216 EUR |
|
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of RRAD antibody, catalog no. 70R-5797 |
|||
RRAD Blocking Peptide |
|||
| 20-abx063234 | Abbexa |
|
|
Polyclonal RRAD Antibody |
|||
| APR05556G | Leading Biology | 0.1ml | 580.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human RRAD . This antibody is tested and proven to work in the following applications: |
|||
RRAD Conjugated Antibody |
|||
| C37229 | SAB | 100ul | 476.4 EUR |
Chang Liver (HeLa) |
|||
| C0050007 | Addexbio | One Frozen vial | 651.6 EUR |
HeLa Antigen Concentrate |
|||
| F813X | Cygnus Technologies | 1 ml | 632.4 EUR |
|
Description: HeLa Antigen Concentrate by Cygnus Technologies is available in Europe via Gentaur. |
|||
HeLa Membrane Lysate |
|||
| XBL-10439 | ProSci | 0.1 mg | 619.8 EUR |
|
Description: Hela (Human cervix Adenocarcinoma) cell membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The Hela (Human cervix Adenocarcinoma) cell was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated Hela (cervix Adenocarcinoma) cell membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated Hela (cervix Adenocarcinoma) cell membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
|||
Hela Nuclear Extract |
|||
| X12001 | EpiGentek | 1000 µg | Ask for price |
HeLa Nuclear Extract |
|||
| 1641-01 | Biovision | each | 222 EUR |
HeLa Nuclear Extract |
|||
| 1641-1 | Biovision | each | 405.6 EUR |
RRAD ORF Vector (Human) (pORF) |
|||
| ORF031832 | ABM | 1.0 ug DNA | 486 EUR |
Gene Knock-Out HR Targeting Vector w/Single Selection Marker (Blasticidin) and Negative Selection (TK) Against Random Integration |
|||
| HR720PA-1 | SBI | 10 µg | 1374 EUR |
293AAV Cell Line |
|||
| AAV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area. |
|||
293AD Cell Line |
|||
| AD-100 | Cell Biolabs | 1 vial | 553.2 EUR |
|
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area. |
|||
293LTV Cell Line |
|||
| LTV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area. |
|||
293RTV Cell Line |
|||
| RV-100 | Cell Biolabs | 1 vial | 609.6 EUR |
|
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area. |
|||
Rrad sgRNA CRISPR Lentivector set (Rat) |
|||
| K7052701 | ABM | 3 x 1.0 ug | 406.8 EUR |
Rrad sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3480701 | ABM | 3 x 1.0 ug | 406.8 EUR |
GAS Reporter (Luc) - HeLa Cell Line (IFNγ/JAK/STAT1 Pathway) |
|||
| 79041 | BPS Bioscience | 2 vials | 1810 EUR |
|
Description: The GAS reporter (Luc)-HeLa cell line is designed to monitor the activity of interferon gamma-induced signal transduction pathways in cultured cells by measuring activated STAT1 homodimers. It contains a firefly luciferase gene driven by three copies of the interferon gamma-activated sites (GAS) located upstream of the minimal TATA promoter. IFNγ first binds to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2). Two STAT1 molecules associate with this ligand-activated receptor complex and are activated by phosphorylation to form active homodimer. The active STAT1 homodimers translocate to the nucleus where they bind interferon gamma-activated sites (GAS) in the promoter of IFNγ inducible genes, including luciferase reporter gene. |
|||
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (GFP+Puro) and Negative Selection (TK) Against Random Integration |
|||
| HR700PA-1 | SBI | 10 µg | 1374 EUR |
Gene Knock-Out HR Targeting Vector w/Dual Selection Markers (RFP+Hygro) and Negative Selection (TK) Against Random Integration |
|||
| HR710PA-1 | SBI | 10 µg | 1374 EUR |
293/GFP Cell Line |
|||
| AKR-200 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
T47D/GFP Cell Line |
|||
| AKR-208 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
A549/GFP Cell Line |
|||
| AKR-209 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
NIH3T3/GFP Cell Line |
|||
| AKR-214 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
NIH3T3/Cas9 Cell Line |
|||
| AKR-5104 | Cell Biolabs | 1 vial | 686.4 EUR |
293/Cas9 Cell Line |
|||
| AKR-5110 | Cell Biolabs | 1 vial | 686.4 EUR |
TARGATT? Knock-in iPSC Genotyping Kit |
|||
| AST-1102 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Doxorubicin Stimulated |
|||
| HCL-2004 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Etoposide Stimulated |
|||
| HCL-2005 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Nocodozole Stimulated |
|||
| HCL-2006 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - TNFa Stimulated |
|||
| HCL-2007 | Alpha Diagnostics | 100ug | 270 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Doxorubicin Stimulated |
|||
| HCL-2010 | Alpha Diagnostics | 100ug | 255.6 EUR |
Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Etoposide Stimulated |
|||
| HCL-2011 | Alpha Diagnostics | 100ug | 255.6 EUR |
RRAD Recombinant Protein (Rat) |
|||
| RP226925 | ABM | 100 ug | Ask for price |
RRAD Recombinant Protein (Mouse) |
|||
| RP169340 | ABM | 100 ug | Ask for price |
HeLa HCP ELISA Kit |
|||
| F810 | Cygnus Technologies | 1 kit (96 wells plate) | 1296 EUR |
|
Description: HeLa HCP ELISA Kit by Cygnus Technologies is available in Europe via Gentaur. |
|||
Anti-HeLa: HRP Conjugate |
|||
| F811 | Cygnus Technologies | 12 ml | 678 EUR |
|
Description: Anti-HeLa: HRP Conjugate by Cygnus Technologies is available in Europe via Gentaur. |
|||
Hela-RFP stable cells |
|||
| SC031-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 930 EUR |
|
Description: RFP expression stable cell line in Hela cells with Puromycin marker. |
|||
Native Nucleosome (HeLa-derived) |
|||
| 52039 | BPS Bioscience | 0.6 mg | 695 EUR |
|
Description: Native nucleosome purified from human HeLa cells. |
|||
Microplate Swing-Out Centrifuge |
|||
| abx725026-1Unit | Abbexa | 1 Unit | 1771.2 EUR |
Clinical Swing-Out Centrifuge |
|||
| abx725027-1Unit | Abbexa | 1 Unit | 1771.2 EUR |
Gene Knock-Out HR Targeting Vector with TK selection [MCS1-LoxP-EF1?-GFP-T2A-Puro-P2A-hsvTK-pA-LoxP-MCS2] |
|||
| HR210PA-1 | SBI | 10 ug | 1374 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7052702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7052703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7052704 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3480702 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3480703 | ABM | 1.0 ug DNA | 184.8 EUR |
Rrad sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3480704 | ABM | 1.0 ug DNA | 184.8 EUR |
SKOV-3/Luc Cell Line |
|||
| AKR-232 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: SKOV-3/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
MCF-7/Luc Cell Line |
|||
| AKR-234 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: MCF-7/Luc Cell Line stably expresses luciferase and otherwise exhibits the same characteristics of the parental cell line. |
|||
OVCAR-5/RFP Cell Line |
|||
| AKR-254 | Cell Biolabs | 1 vial | 686.4 EUR |
|
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line. |
|||
TARGATT? Knock-in iPSC Quick Knockin Kit |
|||
| AST-1101 | Applied StemCell | 1 Kit | Ask for price |
|
Description: 12 month |
|||
Rrad ORF Vector (Rat) (pORF) |
|||
| ORF075643 | ABM | 1.0 ug DNA | 607.2 EUR |
Rrad ORF Vector (Mouse) (pORF) |
|||
| ORF056448 | ABM | 1.0 ug DNA | 607.2 EUR |
Anti-RRAD (aa36-48) antibody |
|||
| STJ72757 | St John's Laboratory | 100 µg | 430.8 EUR |
Anti-HeLa HCP, Affinity Purified |
|||
| HL59/73-AF | Cygnus Technologies | 1 mg | 2295.6 EUR |
|
Description: Anti-HeLa HCP, Affinity Purified by Cygnus Technologies is available in Europe via Gentaur. |
|||
HeLa HCP Std. A-H |
|||
| F813 | Cygnus Technologies | 1 ml | 585.6 EUR |
|
Description: HeLa HCP Std. A-H by Cygnus Technologies is available in Europe via Gentaur. |
|||
Hela-GFP stable cells (Blasticidin) |
|||
| SC034-Bsd | GenTarget | 2 x 106 cell/ml x 1ml | 930 EUR |
|
Description: GFP expression stable cell line in Hela cells with Blasticidin marker. |
|||
Hela-GFP stable cells (Puromycin) |
|||
| SC034-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 930 EUR |
|
Description: GFP expression stable cell line in Hela cells with Puromycin marker. |
|||
Hela-TetR (Puro) stable cells |
|||
| SC035-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 1452 EUR |
|
Description: tetracycline repressor expression Hela stable cell line with Puromycin marker |
|||
HeLa Nuclear Extract (DTT-free) |
|||
| 7947-01 | Biovision | each | 222 EUR |
HeLa Nuclear Extract (DTT-free) |
|||
| 7947-1 | Biovision | each | 379.2 EUR |
RRAD Protein Vector (Human) (pPB-C-His) |
|||
| PV127326 | ABM | 500 ng | 662.4 EUR |
RRAD Protein Vector (Human) (pPB-N-His) |
|||
| PV127327 | ABM | 500 ng | 662.4 EUR |
RRAD Protein Vector (Human) (pPM-C-HA) |
|||
| PV127328 | ABM | 500 ng | 662.4 EUR |
RRAD Protein Vector (Human) (pPM-C-His) |
|||
| PV127329 | ABM | 500 ng | 662.4 EUR |
Human HeLa-S3 (Cervix Epithelioid Carcinoma) lysate |
|||
| HCL-1201 | Alpha Diagnostics | 100ug | 285.6 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2069905 | ABM | 3 x 1.0 ug | 451.2 EUR |
Swing-out rotor 6-place |
|||
| CEN0179 | Scientific Laboratory Supplies | EACH | 607.62 EUR |
Swing-out rotor 8-place |
|||
| CEN0180 | Scientific Laboratory Supplies | EACH | 701.1 EUR |
Swing-out rotor 12-place |
|||
| CEN0181 | Scientific Laboratory Supplies | EACH | 531.24 EUR |
Rotor Swing out 6x5ml RB |
|||
| CEN2634 | Scientific Laboratory Supplies | EACH | 429.78 EUR |
Rotor Swing out 2x3MTP ID |
|||
| CEN2664 | Scientific Laboratory Supplies | EACH | 1299.6 EUR |
Autoclave Print-Out PAPER CR70 |
|||
| SXP374 | Scientific Laboratory Supplies | EACH | 40.7 EUR |
Platinum-E Retroviral Packaging Cell Line, Ecotropic |
|||
| RV-101 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-E cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Platinum-A Retroviral Packaging Cell Line, Amphotropic |
|||
| RV-102 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-A cells contain gag, pol and env genes, allowing retroviral packaging with a single plasmid transfection. |
|||
Platinum-GP Retroviral Packaging Cell Line, Pantropic |
|||
| RV-103 | Cell Biolabs | 1 vial | 1104 EUR |
|
Description: Conventional cells used for retrovirus packaging, such as those based on NIH3T3 cells, have limited stability and produce relatively low yields of retrovirus, mainly due to the poor expression of retroviral structure proteins (gag, pol and env) in the cells. The Platinum Retroviral Packaging Cell Lines are based on the 293T cell line. They exhibit longer stability and produce higher yields of retroviral structure proteins. Plat-GP cells contain the gag and pol genes required for retroviral packaging; an expression vector is co-transfected with a VSVG envelope vector. |
|||
Total Protein - Murine Embryonic Stem Cell Line D3 |
|||
| CBA-305 | Cell Biolabs | 500 ?g | 414 EUR |
|
Description:
|
|||
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K2069906 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K2069907 | ABM | 1.0 ug DNA | 200.4 EUR |
RRAD sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K2069908 | ABM | 1.0 ug DNA | 200.4 EUR |
Human GTP-binding protein RAD (RRAD) ELISA Kit |
|||
| abx385354-96tests | Abbexa | 96 tests | 1093.2 EUR |
Human GTP- binding protein RAD, RRAD ELISA KIT |
|||
| ELI-35549h | Lifescience Market | 96 Tests | 988.8 EUR |
GTP-Binding Protein RAD (RRAD) Antibody |
|||
| 20-abx008742 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
| abx332370-100ul | Abbexa | 100 ul | 510 EUR |
GTP-binding protein RAD (RRAD) Antibody |
|||
| 20-abx241706 | Abbexa |
|
|
GTP-binding protein RAD (RRAD) Antibody |
|||
| 20-abx324872 | Abbexa |
|
|
GTP-Binding Protein RAD (RRAD) Antibody |
|||
| abx432011-200ul | Abbexa | 200 ul | 460.8 EUR |
GTP-binding protein RAD (RRAD) Antibody |
|||
| 20-abx214509 | Abbexa |
|
|
HeLa Nuclear Extract (Epithelioid carcinoma cells) |
|||
| NHELA-100 | Alpha Diagnostics | 100 ug | 196.8 EUR |
HeLa Nuclear Extract (Epithelioid carcinoma cells) |
|||
| NHELA-50 | Alpha Diagnostics | 50 ug | 153.6 EUR |
Luciferase (firefly), Hela stable cells (Blasticidin) |
|||
| SC032-Bsd | GenTarget | 2 x 106 cell/ml x 1ml | 1452 EUR |
|
Description: Luciferase (firefry) expression stable cell line in Hela cells with Blasticidin marker. |
|||
Luciferase (firefly), Hela stable cells (Puromycin) |
|||
| SC032-Puro | GenTarget | 2 x 106 cell/ml x 1ml | 1452 EUR |
|
Description: Luciferase (firefry) expression stable cell line in Hela cells with Puromycin marker. |
|||
Hela-rtTA (GFP-Bsd) stable cells |
|||
| SC038-GB | GenTarget | 2 x 106 cell/ml x 1ml | 1974 EUR |
|
Description: rtTA (reverse tetracycline Transcriptional Activator) expression Hela stable cell line with GFP-Blasticidin fusion dual marker |
|||
Hela-rtTA (GFP-Puro) stable cells |
|||
| SC038-GP | GenTarget | 2 x 106 cell/ml x 1ml | 1974 EUR |
|
Description: rtTA (reverse tetracycline Transcriptional Activator) expression Hela stable cell line with GFP-Puromycin fusion dual marker |
|||
However, once we additional carried out a sensitivity analysis, FPRP, and BFDP take a look at, less-credible optimistic outcomes had been recognized (all FPRP > 0.2 and BFDP > 0.8) in any important affiliation.In abstract, this research strongly signifies that every one important associations had been much less credible optimistic outcomes, fairly than from true associations.